RE:RE:RE:RE:Antibody-Drug-Conjugate (ADC) company reports patient death August 02, 2023 - Researchers have characterized treatment-related adverse events (TRAEs) reported in clinical trials of antibody-drug conjugates (ADCs).
Findings show that patients with breast cancer had the highest rate of all-grade TRAEs, and those with lymphoma had the highest rate of grade 3 or higher TRAEs.
The ADC with the highest rate of allgrade TRAEs was trastuzumab deruxtecan (Enhertu), and the ADC with the highest rate of grade 3 or higher TRAEs was brentuximab vedotin (Adcetris).
Grade 3 or higher drug-related AEs were experienced by 46% of patients treated with trastuzumab deruxtecan. The most common grade 3 or greater AE was neutropenia (19%). Drug-related interstitial lung disease (ILD), which has emerged with this agent in other trials, occurred in 26% of patients, and resulted in death for 2 patients.